Symcel secures €3.6 million Horizon 2020 Phase II grant
Multi-resistant bacterial sepsis infections to be validated utilising sensitive screening technology
21-Nov-2017 -
Symcel, the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, calScreener™, has secured €3.572 million Horizon 2020 funding to support the company’s evaluation of improved combination testing of antibiotics against extensively drug-resistant ...
antibiotic resistance
antibiotics
antimicrobial resistance
+4